Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rydapt

National Institute for Health and Care Excellence NICE logo

NICE backs PTC’s muscular dystrophy drug Translarna

Drug to be available on the NHS for DMD patients aged five and over

Novartis Gehry Building

New drugs help Novartis shrug off Gleevec competition

However, warns of lesser profits this year as firm looks to boost promotion of Entresto

- PMLiVE

Juno cleared to restart CAR-T trial after deaths

Study attributes fatalities to pre-conditioning therapy, not the cancer immunotherapy

Deal Watch June 2016

Allergan, Novartis and Merck & Co are among those featured in this month's round-up of pharma deal activity

Eli Lilly HQ

Lilly and Boehringer combine breast cancer drugs in trial

Firms anticipate together the two drugs will offer a “more complete pathway interference”

- PMLiVE

Novartis gets FDA panel backing for biosimilar Enbrel

However Amgen claims patent protection for the psoriatic arthritis therapy is valid until 2029

National Institute for Health and Care Excellence NICE logo

NICE approves UCB Pharma’s Cimzia

New guidance could significantly extend the patient population it could treat

- PMLiVE

Pfizer warns against price-cutting after NICE backs Bosulif

Cancer drug is the first to be re-appraised form the CDF

Bristol-Myers Squibb (BMS) building

NICE ‘no’ for Opdivo in kidney cancer

BMS oncology drug knocked-back in draft guidance

Novartis plots digital transformation in medical education

Outlines benefits of greater use of technology, including transparency and reach

- PMLiVE

NICE finally set to back wider use of Ferring’s Firmagon

And acknowledges drug's benefits for prostate cancer that spreads to the spine

Roche Basel Switzerland

Roche’s MS drug Ocrevus awarded priority review by FDA

Comes as Swiss company files the therapy with the FDA and EMA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links